1-7 of 7
Gautham Borthakur
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I Open Label Study of Fostamatinib, a SYK Inhibitor, in Patients with Lower-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Guillermo Montalban-Bravo, Gautham Borthakur, Kelly S. Chien, Danielle Hammond, Rajani K Medury, Jane Waukau, Sherry A. Pierce, Hagop Kantarjian, Guillermo Garcia-Manero
Journal: Blood
Blood (2022) 140 (Supplement 1): 9816–9817.
https://doi.org/10.1182/blood-2022-170185
Published: 2022
Journal Articles

Incidence of Central Nervous System Toxicity and Cytokine Release Syndrome in Leukemia Patients Treated with Blinatumomab

Elias Jabbour, Shilpa Paul, Dan E. Nichols, Faezeh Darbaniyan, Jenessa Lee, Koji Sasaki, Nicholas Short, Nitin Jain, Farhad Ravandi, Guillermo Garcia-Manero, Tapan M. Kadia, Guillermo Montalban-Bravo, Gautham Borthakur, Rebecca Garris, Marina Konopleva, Hagop Kantarjian
Journal: Blood
Blood (2022) 140 (Supplement 1): 11663–11665.
https://doi.org/10.1182/blood-2022-170579
Published: 2022
Journal Articles

Clinical Characteristics and Outcomes of Patients Diagnosed with Acute Myeloid Leukemia with Expression of CD71

Daniel Rivera, Yesid Alvarado, Guillermo Garcia-Manero, Gautham Borthakur, Hagop Kantarjian, Sergej Konoplev
Journal: Blood
Blood (2021) 138 (Supplement 1): 4449.
https://doi.org/10.1182/blood-2021-151023
Published: 2021
Journal Articles

General Characteristics and Association of Myeloid Neoplasm with Thyroid Cancer

Shehab Fareed Mohamed, Naveen Pemmaraju, Koji Sasaki, Gautham Borthakur, Tareq Abuasba, Maliha Khan, Hyunsoo Hwang, Xuemei Wang, Srdan Verstovsek, Naifa Busaidy
Journal: Blood
Blood (2021) 138 (Supplement 1): 4634.
https://doi.org/10.1182/blood-2021-148867
Published: 2021
Journal Articles

Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Daniel Rivera, Tapan M. Kadia, Guillermo Montalban-Bravo, Stefan Faderl, Koji Sasaki, Nicholas J. Short, Naval Daver, Courtney D. DiNardo, Lucia Masarova, Alessandra Ferrajoli, Elias J. Jabbour, Gautham Borthakur, Hind Al Azzawi, Marina Konopleva, Guillermo Garcia-Manero, Michael Andreeff, Hagop Kantarjian, Farhad Ravandi, Yesid Alvarado
Journal: Blood
Blood (2021) 138 (Supplement 1): 2323.
https://doi.org/10.1182/blood-2021-149840
Published: 2021
Journal Articles

Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Jorge M. Ramos Perez, Tapan M. Kadia, MD, Guillermo Montalban-Bravo, MD, Stefan Faderl, MD, Koji Sasaki, MD, Naval Daver, MD, Courtney D. DiNardo, MD MSCE, Lucia Masarova, MD, Alessandra Ferrajoli, MD, Elias Jabbour, MD, Gautham Borthakur, Hind Al Azzawi, Naveen Pemmaraju, MD, Marina Konopleva, MD PhD, Sherry A. Pierce, BSN, BA, Guillermo Garcia-Manero, MD, Michael Andreeff, MD PhD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Yesid Alvarado, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 32–34.
https://doi.org/10.1182/blood-2020-142570
Published: 2020
Journal Articles

Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls

Clinical Trials & Observations
Srdan Verstovsek, Hagop M. Kantarjian, Zeev Estrov, Jorge E. Cortes, Deborah A. Thomas, Tapan Kadia, Sherry Pierce, Elias Jabbour, Gautham Borthakur, Elisa Rumi, Ester Pungolino, Enrica Morra, Domenica Caramazza, Mario Cazzola, Francesco Passamonti
Journal: Blood
Blood (2012) 120 (6): 1202–1209.
https://doi.org/10.1182/blood-2012-02-414631
Published: 2012